Recent developments in the pharmacological treatment and prevention of corneal graft rejection

Area of Science:

• Ophthalmology
• Immunology
• Transplantation Science

Background:

• Corneal transplantation exhibits high initial success but poor long-term survival due to graft rejection.
• Immune privilege in the cornea does not prevent allograft failure, which remains the primary cause of graft loss.
• Current immunosuppressive therapies show limited success, mirroring challenges seen in solid organ transplantation.

Purpose of the Study:

• To review existing data on immunosuppression in corneal transplantation.
• To discuss the immunobiology underlying corneal graft rejection.
• To propose novel therapeutic strategies for improving corneal allograft survival.

Main Methods:

• Literature review of clinical trials and immunological studies.
• Analysis of data on immunosuppressive efficacy and patient outcomes.
• Synthesis of current understanding of corneal immune privilege and rejection mechanisms.

Main Results:

• Limited clinical trial data restricts definitive conclusions on immunosuppression.
• Corneal graft rejection is a significant barrier to long-term allograft survival.
• Emerging research highlights new therapeutic targets based on immunobiology.

Conclusions:

• Optimizing immunosuppression remains critical for enhancing corneal transplant success.
• Further research into corneal graft immunology is essential for developing effective treatments.
• Novel immunomodulatory therapies hold promise for reducing rejection and improving long-term outcomes.